Technology enabling the largest free and accessible event worldwide on COVID-19 management: experience report: Tecnologia viabilizando o maior evento gratuito e acessível do mundo sobre gestão da COVID-19: relato de experiência

Introdução: O uso das redes sociais como fonte de informação durante a pandemia de Covid-19 possibilitou o acesso do grande público a informações atualizadas, mas também permitiu uma intensa disseminação de notícias falsas no Brasil e no mundo. Objetivo: Este relatório tem como objetivo apresentar a experiência da tecnologia que possibilita a organização e implantação de um evento científico online gratuito de grande escala sobre a Covid-19, com foco em informações baseadas em evidências, atendimento e gestão do paciente. Métodos: O "Primeiro Congresso Brasileiro de Evidências Clínicas sobre Covid-19" aconteceu entre os dias 03 e 07 de maio de 2021 e foi realizado pela Universidade Federal de Minas Gerais, a principal universidade federal do Brasil. Resultados: Houve 27.102 cadastros. A transmissão teve 29.170 visualizações no primeiro dia. Em 25 de junho de 2021, foram 80.923 visualizações para a versão original em áudio e 10.352 visualizações para a tradução simultânea. Os tópicos compreenderam prevenção da Covid-19, gestão na atenção primária, atendimento pré-hospitalar, assistência hospitalar, unidade de terapia intensiva, longa-COVID-19, vacinas, saúde mental e custos. Minipalestras foram seguidas de discussão e interação com os participantes. Palestrantes e moderadores de todo o Brasil e do exterior foram escolhidos de acordo com sua expertise em temas de Covid-19 e em medicina baseada em evidências. Entre as sessões, foram apresentados depoimentos em vídeo de pessoas que não puderam trabalhar em casa sobre o que tocou seu coração durante a pandemia. A acessibilidade foi garantida por meio de tradução simultânea para a Língua Brasileira de Sinais. A satisfação dos participantes foi avaliada, com 2.228 respondentes, dos quais 97,4% disseram que suas expectativas foram superadas e 86,8% relataram adquirir novos conhecimentos sobre a Covid-19. Final considerations: Essa experiência mostrou que a tecnologia possibilitou a divulgação de evidências científicas acessíveis sobre a Covid-19 para um grande público por meio de um evento online gratuito

Clinical characteristics and outcomes of hospital-manifested COVID-19 among Brazilians

ABSTRACT: Objectives: To analyze the clinical characteristics and outcomes of admitted patients with the hospital- versus community-manifested COVID-19 and to evaluate the risk factors related to mortality in the first population. Methods: This retrospective cohort included consecutive adult patients with COVID-19, hospitalized between March and September 2020. The demographic data, clinical characteristics, and outcomes were extracted from medical records. Patients with hospital-manifested COVID-19 (study group) and those with community-manifested COVID-19 (control group) were matched by the propensity score model. Logistic regression models were used to verify the risk factors for mortality in the study group. Results: Among 7,710 hospitalized patients who had COVID-19, 7.2% developed symptoms while admitted for other reasons. Patients with hospital-manifested COVID-19 had a higher prevalence of cancer (19.2% vs 10.8%) and alcoholism (8.8% vs 2.8%) than patients with community-manifested COVID-19 and also had a higher rate of intensive care unit requirement (45.1% vs 35.2%), sepsis (23.8% vs 14.5%), and death (35.8% vs 22.5%) (P <0.05 for all). The factors independently associated with increased mortality in the study group were increasing age, male sex, number of comorbidities, and cancer. Conclusion: Hospital-manifested COVID-19 was associated with increased mortality. Increasing age, male sex, number of comorbidities, and cancer were independent predictors of mortality among those with hospital-manifested COVID-19 disease

Development and validation of the MMCD score to predict kidney replacement therapy in COVID-19 patients

Abstract Background Acute kidney injury (AKI) is frequently associated with COVID-19, and the need for kidney replacement therapy (KRT) is considered an indicator of disease severity. This study aimed to develop a prognostic score for predicting the need for KRT in hospitalised COVID-19 patients, and to assess the incidence of AKI and KRT requirement. Methods This study is part of a multicentre cohort, the Brazilian COVID-19 Registry. A total of 5212 adult COVID-19 patients were included between March/2020 and September/2020. Variable selection was performed using generalised additive models (GAM), and least absolute shrinkage and selection operator (LASSO) regression was used for score derivation. Accuracy was assessed using the area under the receiver operating characteristic curve (AUC-ROC). Results The median age of the model-derivation cohort was 59 (IQR 47–70) years, 54.5% were men, 34.3% required ICU admission, 20.9% evolved with AKI, 9.3% required KRT, and 15.1% died during hospitalisation. The temporal validation cohort had similar age, sex, ICU admission, AKI, required KRT distribution and in-hospital mortality. The geographic validation cohort had similar age and sex; however, this cohort had higher rates of ICU admission, AKI, need for KRT and in-hospital mortality. Four predictors of the need for KRT were identified using GAM: need for mechanical ventilation, male sex, higher creatinine at hospital presentation and diabetes. The MMCD score had excellent discrimination in derivation (AUROC 0.929, 95% CI 0.918–0.939) and validation (temporal AUROC 0.927, 95% CI 0.911–0.941; geographic AUROC 0.819, 95% CI 0.792–0.845) cohorts and good overall performance (Brier score: 0.057, 0.056 and 0.122, respectively). The score is implemented in a freely available online risk calculator ( https://www.mmcdscore.com/ ). Conclusions The use of the MMCD score to predict the need for KRT may assist healthcare workers in identifying hospitalised COVID-19 patients who may require more intensive monitoring, and can be useful for resource allocation